Company Encyclopedia
View More
name
Kronos Bio
KRON.US
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
1.946 T
KRON.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking0/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-59.49%E
    • Profit Margin-701.53%E
    • Gross Margin100.00%A
  • Growth ScoreB
    • Revenue YoY21.15%A
    • Net Profit YoY44.60%B
    • Total Assets YoY-40.90%E
    • Net Assets YoY-41.73%E
  • Cash ScoreC
    • Cash Flow Margin-14.25%D
    • OCF YoY21.15%A
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreB
    • Gearing Ratio26.20%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kronos Worldwide, Inc. Reports Third Quarter 2025 Results

    Dallas, Texas, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- November 6, 2025…Kronos Worldwide, Inc. ( NYSE:KRO ) today reported a net loss of $37.0 million, or $.32 per share, in the third quarter of 2025 compared to net income of $71.8 million, or $.62 per share, in the third quarter of 2024.

    GlobeNewswire·
    US
    KRO
    -2.05%
    US
    KRON
    0.00%
    GlobeNewswire·
    US
    KRO
    -2.05%
    US
    KRON
    0.00%

    Kronos Worldwide Inc. Announces €75 Million Private Placement of Senior Secured Notes Due 2029

    Kronos Worldwide, Inc. has announced a private offering of €75 million in additional 9.50% Senior Secured Notes due 2029. This offering extends the existing €351,174,000 of similar notes. The new notes will have the same terms as the existing ones and are guaranteed by the company and its domestic subsidiaries. Proceeds will be used to pay off 3.75% Senior Secured Notes due September 2025 or repay amounts drawn from its credit facility with Wells Fargo, with any additional funds for general corporate purposes.

    Reuters·
    US
    KRO
    -2.05%
    US
    KRON
    0.00%
    Reuters·
    US
    KRO
    -2.05%
    US
    KRON
    0.00%

    Kronos Bio Inc. Completes Merger with Concentra Biosciences, Becoming a Wholly Owned Subsidiary

    Kronos Bio Inc. has completed its merger with Concentra Biosciences, LLC, with Concentra's subsidiary acquiring approximately 72.90% of Kronos Bio's shares at $0.57 each. The merger was finalized on June 20, 2025, making Kronos Bio a wholly owned subsidiary of Concentra. The tender offer expired on June 18, 2025.

    Reuters·
    US
    KRON
    0.00%
    Reuters·
    US
    KRON
    0.00%

    Deborah Knobelman, President & Interim CEO, Reports Disposal of Kronos Bio Inc. Common Shares

    Deborah Knobelman, President & Interim CEO of Kronos Bio Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    KRON
    0.00%
    Reuters·
    US
    KRON
    0.00%

    Investor rights law firm probes KRON, AXL, TASK, STRR for securities law violations, fiduciary duty breaches. NY, May 28, 2025.

    Halper Sadeh LLC is investigating Kronos Bio, Inc. (NASDAQ: KRON) and other companies for potential breaches of fiduciary duties and violations of federal securities laws. This investigation highlights concerns over shareholder protection in mergers and acquisitions. Further details will be provided as the probe continues.

    Unusual Whales·
    US
    KRON
    0.00%
    Unusual Whales·
    US
    KRON
    0.00%
    © 2025 Longbridge｜Disclaimer